InMed Pharmaceuticals Inc Investor Summit Transcript
Hello, everyone, and welcome to the Investor Summit presentation. Presenting now is Eric Adams, CEO of InMed Pharmaceuticals.
Eric, I'm going to let you go ahead and get started.
Great. Thanks so much. Good to be here. InMed is a publicly traded company on the Nasdaq. Our symbol is INM, and as such, it's important that people understand that we will be using forward-looking statements in today's presentation.
So who is InMed Pharmaceuticals? We are a pure-play rare cannabinoid company. So we focus on a class of compounds called cannabinoids, and we're developing those for a number of different diseases with unmet medical needs. InMed follows the traditional clinical trial and FDA approval pathway. So we're just the same as any other pharmaceutical company, just at a smaller scale, but we are currently in human clinical trials.
We have several different capabilities in-house. We have a drug discovery capability, where we are developing a pipeline of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |